The cost of whole genome sequencing (WGS) is quietly crossing critical thresholds. The $1,000+ test has now broken previously unheard price barriers and is still falling.
At current price points, WGS is no longer a future concept. It becomes a practical, scalable diagnostic tool.
We are already seeing accelerating demand for clinical NGS across oncology, rare diseases, and preventive medicine. The appeal is obvious: a “one test for all” strategy that replaces fragmented panels with a single, comprehensive dataset that is captured once and re-analysed indefinitely.
This shift raises an important question. Are we optimizing for sequencing cost, or total system cost?
As sequencing becomes commoditized, the real bottlenecks move downstream:
• Data storage at population scale
• Bioinformatics pipelines and interpretation
• Clinical integration and reporting
In oncology, the conversation is already evolving. Breadth (WGS) is powerful, but in many scenarios, depth still matters more. Ultra-deep, targeted sequencing remains essential for sensitivity in tumor profiling, detecting clonal evolution, single-cell sequencing, spatial genomics and applications like minimal residual disease, where sensitivity is everything.
Turnaround time (TAT) is also an important consideration in modern oncology, where a test that returns results in 7 days and changes therapy, is more valuable than one that is more comprehensive, but has a TAT of 21 or more days and is too late to change therapy that has already commenced. A subtle but important shift in oncology is moving away from getting the most comprehensive genomic data to getting the right data fast enough to act. The use of targeted panels and ctDNA are thus becoming dominant in the field. For some entities, even very specific testing using real time PCR is favoured. WGS may be considered somewhat niche in impacting clinical decision. In oncology a key message is "Fast enough to act beats perfect but late".
As WGS enters the clinical space, validation, accreditation and meeting other regulatory challenges may become a key bottleneck.
